New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

abstract：:In the last decade, transdermal delivery of testosterone (T) has been shown to be a safe and effective means of treating male hypogonadism. Transdermal T patches can provide for physiologic androgen replacement in over 90% of men with hypogonadism. In addition, T patches have been shown to be equivalent to im. T ester...

journal_title：Expert opinion on investigational drugs

authors： Amory JK,Matsumoto AM

更新日期：1998-12-01 00:00:00

abstract：INTRODUCTION:Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The development of acquired resistance to crizotinib represents an ongoing...

journal_title：Expert opinion on investigational drugs

authors： Karachaliou N,Santarpia M,Gonzalez Cao M,Teixido C,Sosa AE,Berenguer J,Rodriguez Capote A,Altavilla G,Rosell R

更新日期：2017-06-01 00:00:00

abstract：:With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

journal_title：Expert opinion on investigational drugs

authors： Schultze JL

更新日期：1999-12-01 00:00:00

abstract：INTRODUCTION:Glioblastoma is a primary brain tumor with a poor prognosis despite multimodal therapy including surgery, radiotherapy and alkylating chemotherapy. Novel therapeutic options are therefore urgently needed; however, there have been various drug failures in late-stage clinical development. The proteasome repr...

journal_title：Expert opinion on investigational drugs

authors： Roth P,Mason WP,Richardson PG,Weller M

更新日期：2020-10-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) incidence in the United States increases with age. Given the progressive ageing of the general population, incidence of these diseases is likely to continue to rise in the future. There is an acute need for therapeutic developments ...

journal_title：Expert opinion on investigational drugs

authors： Epling-Burnette PK,Loughran TP Jr

更新日期：2010-05-01 00:00:00

abstract：:A disintegrin and metalloproteases (ADAMs) are zinc-dependent trans-membrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway ...

journal_title：Expert opinion on investigational drugs

authors： Zhou BB,Fridman JS,Liu X,Friedman SM,Newton RC,Scherle PA

更新日期：2005-06-01 00:00:00

abstract：INTRODUCTION:Stroke is the second leading cause of death worldwide and the leading cause of adult neurological disability. Despite advances in stroke unit care, and increasing use of thrombolysis, there remains an urgent need for safe and effective treatments for acute ischaemic stroke. However, this is against a backd...

journal_title：Expert opinion on investigational drugs

authors： Smith CJ,Denes A,Tyrrell PJ,Di Napoli M

更新日期：2015-05-01 00:00:00

abstract：:Immunosuppressant drugs are crucial in order to protect transplanted kidney, heart or liver against the body's natural defence mechanisms. These drugs are used to prevent both acute rejection of the organ as well as chronic deterioration of the graft over longer periods of time. Currently used immunosuppressant drugs ...

journal_title：Expert opinion on investigational drugs

authors： Jorga A,Johnston A

更新日期：2005-03-01 00:00:00

abstract：INTRODUCTION:The addition of monoclonal antibody (mAb) epidermal growth factor receptor (EGFR) inhibitors to classic chemotherapy doublet backbones has improved survival of metastatic colorectal cancer (mCRC). However, the role of triple-drug chemotherapy regimens in combination with an anti-EGFR mAb inhibitor is not y...

journal_title：Expert opinion on investigational drugs

authors： Matos I,Noguerido A,Ros J,Mulet N,Argilés G,Elez É,Tabernero J

更新日期：2019-05-01 00:00:00

abstract：:The introduction of HIV-1 protease inhibitors in 1995 ushered in the era of highly active antiretroviral therapy. For the first time, inhibition of two key enzymes responsible for HIV replication, reverse transcriptase and protease, was possible. The combination of two nucleoside reverse transcriptase inhibitors with ...

journal_title：Expert opinion on investigational drugs

authors： Piliero PJ

更新日期：2002-09-01 00:00:00

abstract：:Early breast carcinoma is defined as pathological stage 1 (pT1N0M0) tumour and its incidence has recently increased possibly due to the advent of mammography based mass screening. Overall survival of these patients is in general excellent, but more than 20% of them will eventually develop distant metastasis and die. T...

journal_title：Expert opinion on investigational drugs

authors： Sasano H

更新日期：2010-04-01 00:00:00

abstract：:Bromocriptine, a potent dopamine D(2) receptor agonist, has been shown to reduce insulin resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and in Phase II studies. Bromocriptine has been used worldwide for over 20 years to treat Parkinson's disease, macroprolactinoma and other disorde...

journal_title：Expert opinion on investigational drugs

authors： Cincotta AH,Meier AH,Cincotta M Jr

更新日期：1999-10-01 00:00:00

abstract：INTRODUCTION:Epidermal growth factor receptor (EGFR) targeted treatment has been evaluated but has not shown a clear clinical benefit for breast cancer. This review article aims to consider the knowledge of the biological background of EGFR pathways in dissecting clinical studies of EGFR targeted treatment in breast ca...

journal_title：Expert opinion on investigational drugs

authors： Matsuda N,Lim B,Wang X,Ueno NT

更新日期：2017-04-01 00:00:00

abstract：:COPD is a chronic disease of the lung that is characterised by decreased air flow and associated abnormal inflammatory responses of the lungs. A total of 80% of COPD incidences are observed in patients with history of smoking tobacco. The chronic condition of COPD is characterised by airway remodelling, which leads to...

journal_title：Expert opinion on investigational drugs

authors： Srivastava PK,Dastidar SG,Ray A

更新日期：2007-07-01 00:00:00

abstract：INTRODUCTION:IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in Phase I - III of clinical development for RA. A...

journal_title：Expert opinion on investigational drugs

authors： Semerano L,Thiolat A,Minichiello E,Clavel G,Bessis N,Boissier MC

更新日期：2014-07-01 00:00:00

abstract：:ATP-gated P2X7 receptors (P2X7) make a unique family of extracellular ATP-activated plasma membrane ion channels expressed in haematopoietic and epithelial cells. They have been extensively studied in immune cells where their activation leads to the rapid release of pro-inflammatory cytokines and the initiation of the...

journal_title：Expert opinion on investigational drugs

authors： Roger S,Pelegrin P

更新日期：2011-07-01 00:00:00

abstract：:Oxcarbazepine (OXC) was introduced in 1990 and is now registered in 54 countries worldwide as monotherapy, as add-on treatment for partial seizures, with or without secondarily generalised seizures, and primary generalised tonic-clonic seizures. OXC and its active metabolite, monohydroxy derivative (MHD), block voltag...

journal_title：Expert opinion on investigational drugs

authors： Schachter SC

更新日期：1999-07-01 00:00:00

abstract：:Endothelin-1 (ET-1) is enhanced and has been demonstrated to be a prognostic marker in patients with advanced stages of heart failure, acute ischaemic syndromes, myocardial infarction and pulmonary hypertension. Activation of the endothelin (ET) system is associated with adverse haemodynamic consequences in patients w...

journal_title：Expert opinion on investigational drugs

authors： Neunteufl T,Berger R,Pacher R

更新日期：2002-03-01 00:00:00

abstract：:Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is t...

journal_title：Expert opinion on investigational drugs

authors： Temsamani J,Pari GS,Guinot P

更新日期：1997-09-01 00:00:00

abstract：INTRODUCTION:Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progres...

journal_title：Expert opinion on investigational drugs

authors： Galimberti D,Scarpini E

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Histone deacetylases (HDACs), which target histones as well as non-histone proteins as substrates, have the potential to regulate aberrant gene expression and restore normal growth control in malignancies. OBJECTIVE:This review provides an updated summary of preclinical and clinical experience with the oral...

journal_title：Expert opinion on investigational drugs

authors： Le Tourneau C,Siu LL

更新日期：2008-08-01 00:00:00

abstract：:Preclinical and clinical evidence support the effectiveness of neurotrophins in Alzheimer's disease (AD) and neurodegenerative diseases. Delivery of neurotrophins to target sites in the brain remains a major obstacle for their use in humans. Development of orally active agents that mimic the effects of nerve growth fa...

journal_title：Expert opinion on investigational drugs

authors： Glasky AJ,Glasky MS,Ritzmann RF,Rathbone MP

更新日期：1997-10-01 00:00:00

abstract：:Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutic...

journal_title：Expert opinion on investigational drugs

authors： Benigni A,Perico N,Remuzzi G

更新日期：2004-11-01 00:00:00

abstract：INTRODUCTION:Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer death. Although in some cases initial treatment is effective, most of the women diagnosed with EOC will probably need medical treatment for their disease. There is a critical need to develop effective new strategies for the managem...

journal_title：Expert opinion on investigational drugs

authors： Morotti M,Becker CM,Menada MV,Ferrero S

更新日期：2013-10-01 00:00:00

abstract：:In order to improve therapy and increase the quality of life for diabetic patients, it has been of significant interest to develop rapid-acting insulin preparations that mimic the physiological meal-time profile of insulin more closely than soluble human insulin. Insulin aspart (B28Asp human insulin) is a novel rapid-...

journal_title：Expert opinion on investigational drugs

authors： Gammeltoft S,Hansen BF,Dideriksen L,Lindholm A,Schäffer L,Trüb T,Dayan A,Kurtzhals P

更新日期：1999-09-01 00:00:00

abstract：INTRODUCTION:GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed. In...

journal_title：Expert opinion on investigational drugs

authors： Garber AJ

更新日期：2012-01-01 00:00:00

abstract：:Targeting cellular proliferation persists as a mainstay of cancer therapeutic strategy. Although microtubule-targeting drugs (such as taxanes and vinca alkaloids) have been used successfully in the clinic to treat a variety of cancers, they carry substantial liabilities that have spurred drug companies to aggressively...

journal_title：Expert opinion on investigational drugs

authors： Miglarese MR,Carlson RO

更新日期：2006-11-01 00:00:00

abstract：INTRODUCTION:Heat shock proteins (Hsps) are part of a complex network of chaperone proteins that are critically involved in the conformational maturation of intracellular proteins and regulate their degradation via the proteasome system Hsps (especially Hsp70 and Hsp90) are upregulated in many cancers and are potential...

journal_title：Expert opinion on investigational drugs

authors： Subramaniam DS,Warner EA,Giaccone G

更新日期：2017-01-01 00:00:00

abstract：:Transcription factors are proteins that regulate gene transcription and expression. In many cases of acute leukaemia chromosomal aberrations are translocations of transcription factors which change their expression and induce the leukaemic phenotype. These abnormal transcription factors are tumour-specific and can be ...

journal_title：Expert opinion on investigational drugs

authors： Douer D

更新日期：2000-02-01 00:00:00

abstract：:This perspective is the second in a series discussing drugs dropped from development in 2006, with a focus on pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. A survey of discontinued drugs from 2006 is provided, based on data from the Pharmaprojects database, along with an analysis of biology,...

journal_title：Expert opinion on investigational drugs

authors： Ozdemir C,Akdis CA

更新日期：2007-09-01 00:00:00